Cognition Therapeutics, Inc. (CGTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cognition Therapeutics, Inc. (CGTX) closed at USD 0.78 on 2026-10-14, a change of -51.1 % over the past year, with a market capitalization of USD 69.67M.

Cognition Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cognition Therapeutics, Inc. key figures

Previous close

USD 0.78 (2026-10-14)

1-year change

-51.1 %

Market cap

USD 69.67M

Enterprise value

USD 36.24M

P/E ratio (trailing)

-4.58

P/E ratio (forward)

-3.33

EPS (trailing)

-0.16

EPS (forward)

-0.22

PEG ratio

n/a

Price to book

2.11

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

18.88

Employees

14

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cognition Therapeutics, Inc. and compare it with other stocks.